NASDAQ:SPRO

Spero Therapeutics Competitors

$12.93
-0.41 (-3.07 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.66
Now: $12.93
$13.49
50-Day Range
$12.80
MA: $15.34
$18.81
52-Week Range
$7.39
Now: $12.93
$23.64
Volume122,396 shs
Average Volume268,157 shs
Market Capitalization$381.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67

Competitors

Spero Therapeutics (NASDAQ:SPRO) Vs. TVTX, IMGN, PRLD, AMTI, OLMA, and PMVP

Should you be buying SPRO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Spero Therapeutics, including Travere Therapeutics (TVTX), ImmunoGen (IMGN), Prelude Therapeutics (PRLD), Applied Molecular Transport (AMTI), Olema Pharmaceuticals (OLMA), and PMV Pharmaceuticals (PMVP).

Travere Therapeutics (NASDAQ:TVTX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Travere Therapeutics and Spero Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Spero Therapeutics00503.00

Travere Therapeutics presently has a consensus price target of $44.3333, suggesting a potential upside of 77.69%. Spero Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Travere Therapeutics.

Earnings and Valuation

This table compares Travere Therapeutics and Spero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

Spero Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Travere Therapeutics and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Spero Therapeutics-768.15%-93.43%-72.17%

Institutional and Insider Ownership

57.6% of Spero Therapeutics shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by insiders. Comparatively, 17.4% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Travere Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Summary

Spero Therapeutics beats Travere Therapeutics on 8 of the 12 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImmunoGen and Spero Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Spero Therapeutics00503.00

ImmunoGen presently has a consensus price target of $10.10, suggesting a potential upside of 34.31%. Spero Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than ImmunoGen.

Earnings and Valuation

This table compares ImmunoGen and Spero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

Spero Therapeutics has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ImmunoGen and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Spero Therapeutics-768.15%-93.43%-72.17%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 3.8% of ImmunoGen shares are owned by insiders. Comparatively, 17.4% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

ImmunoGen has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Summary

Spero Therapeutics beats ImmunoGen on 8 of the 14 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Profitability

This table compares Prelude Therapeutics and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Spero Therapeutics-768.15%-93.43%-72.17%

Institutional and Insider Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 17.4% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Prelude Therapeutics and Spero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

Prelude Therapeutics has higher earnings, but lower revenue than Spero Therapeutics.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prelude Therapeutics and Spero Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
Spero Therapeutics00503.00

Prelude Therapeutics presently has a consensus price target of $54.25, suggesting a potential upside of 68.27%. Spero Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Prelude Therapeutics.

Summary

Spero Therapeutics beats Prelude Therapeutics on 5 of the 9 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Applied Molecular Transport and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Spero Therapeutics-768.15%-93.43%-72.17%

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 17.4% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Molecular Transport and Spero Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

Applied Molecular Transport has higher earnings, but lower revenue than Spero Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and target prices for Applied Molecular Transport and Spero Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Spero Therapeutics00503.00

Applied Molecular Transport presently has a consensus target price of $68.75, suggesting a potential upside of 64.32%. Spero Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Applied Molecular Transport.

Summary

Spero Therapeutics beats Applied Molecular Transport on 5 of the 9 factors compared between the two stocks.

Olema Pharmaceuticals (NASDAQ:OLMA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Olema Pharmaceuticals and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olema PharmaceuticalsN/AN/AN/A
Spero Therapeutics-768.15%-93.43%-72.17%

Insider & Institutional Ownership

57.6% of Spero Therapeutics shares are owned by institutional investors. 17.4% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Olema Pharmaceuticals and Spero Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/AN/AN/AN/A
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

Olema Pharmaceuticals has higher earnings, but lower revenue than Spero Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and target prices for Olema Pharmaceuticals and Spero Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olema Pharmaceuticals00403.00
Spero Therapeutics00503.00

Olema Pharmaceuticals presently has a consensus target price of $60.6667, suggesting a potential upside of 67.87%. Spero Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Olema Pharmaceuticals.

Summary

Spero Therapeutics beats Olema Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

PMV Pharmaceuticals (NASDAQ:PMVP) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for PMV Pharmaceuticals and Spero Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PMV Pharmaceuticals01302.75
Spero Therapeutics00503.00

PMV Pharmaceuticals presently has a consensus target price of $38.00, suggesting a potential upside of 17.39%. Spero Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 153.29%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than PMV Pharmaceuticals.

Profitability

This table compares PMV Pharmaceuticals and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PMV PharmaceuticalsN/AN/AN/A
Spero Therapeutics-768.15%-93.43%-72.17%

Valuation & Earnings

This table compares PMV Pharmaceuticals and Spero Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/AN/AN/AN/A
Spero Therapeutics$18.15 million21.02$-60,920,000.00($3.35)-3.86

PMV Pharmaceuticals has higher earnings, but lower revenue than Spero Therapeutics.

Insider & Institutional Ownership

69.7% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 17.4% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats PMV Pharmaceuticals on 5 of the 9 factors compared between the two stocks.


Spero Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.